16652-71-4Relevant articles and documents
Synthesis and bioactivity of a Goralatide analog with antileukemic activity
Li, Zhiliang,Lebedyeva, Iryna O.,Golubovskaya, Vita M.,Cance, William G.,Alamry, Khalid A.,Faidallah, Hassan M.,Dennis Hall,Katritzky, Alan R.
, p. 5056 - 5060 (2015)
Natural tetrapeptide Goralatide (AcSDKP) is a selective inhibitor of primitive haematopoietic cell proliferation. It is not stable in vivo and decomposes within 4.5 min when applied to live cells. In this work we developed an analog of Goralatide that exhibits cytotoxicity towards human myeloid HL-60, HEL, Nalm-6 leukemia cells, endothelial HUVEC, glioblastoma U251 and transformed kidney 293T cells. The Goralatide analog showed significant stability in organic solution with no tendency to degrade oxidatively.
Design, synthesis and biological evaluation of new bivalent quinazoline analogues as IAP antagonists
Bae, Inhwan,Kim, Daejin,Choi, Jaeyul,Kim, Jisook,Kim, Minjeong,Park, Bokyung,Kim, Young Hoon,Ahn, Young Gil,Hyung Kim, Ha,Kim, Dae Kyong
, (2021/01/26)
We recently reported the biological evaluations of monovalent IAP antagonist 7 with good potency (MDA-MB-231, IC50 = 19 nM). In an effort to increase cellular activity and improve favorable drug-like properties, we newly designed and synthesized bivalent analogues based on quinazoline structure of 7. Optimization of cellular potency and CYP inhibition led to the identification of 27, which showed dramatic increase of over 100-fold (IC50 = 0.14 nM) and caused substantial tumor regressions in MDA-MB-231 xenograft model. These results strongly support 27 as a promising bivalent antagonist for the development of an effective anti-tumor approaches.
Synthesis of Biaryl-Bridged Cyclic Peptides via Catalytic Oxidative Cross-Coupling Reactions
Ben-Lulu, Mor,Gaster, Eden,Libman, Anna,Pappo, Doron
supporting information, p. 4835 - 4839 (2020/02/11)
Biaryl-bridged cyclic peptides comprise an intriguing class of structurally diverse natural products with significant biological activity. Especially noteworthy are the antibiotics arylomycin and its synthetic analogue G0775, which exhibits potent activity against Gram-negative bacteria. Herein, we present a simple, flexible, and reliable strategy based on activating-group-assisted catalytic oxidative coupling for assembling biaryl-bridged cyclic peptides from natural amino acids. The synthetic approach was utilized for preparing a number of natural and unnatural biaryl-bridged cyclic peptides, including arylomycin/G0775 and RP 66453 cyclic cores.